Teva Pharmaceutical Industries Ltd
NYSE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Watchlist
Price: 31 USD 0.16%
Market Cap: 35.1B USD

Teva Pharmaceutical Industries Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Teva Pharmaceutical Industries Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Revenue
$16.8B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Revenue
$19m
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Revenue
₪238.8m
CAGR 3-Years
3%
CAGR 5-Years
93%
CAGR 10-Years
N/A
PolyPid Ltd
NASDAQ:PYPD
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Revenue
$20.9m
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
46%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Revenue
₪300.2m
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
2%
No Stocks Found

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
16.84 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Teva Pharmaceutical Industries Ltd's Revenue?
Revenue
16.8B USD

Based on the financial report for Sep 30, 2025, Teva Pharmaceutical Industries Ltd's Revenue amounts to 16.8B USD.

What is Teva Pharmaceutical Industries Ltd's Revenue growth rate?
Revenue CAGR 10Y
-2%

Over the last year, the Revenue growth was 0%. The average annual Revenue growth rates for Teva Pharmaceutical Industries Ltd have been 3% over the past three years , 1% over the past five years , and -2% over the past ten years .

Back to Top